215 related articles for article (PubMed ID: 30706531)
1. Variation in SIPA1L2 is correlated with phenotype modification in Charcot- Marie- Tooth disease type 1A.
Tao F; Beecham GW; Rebelo AP; Svaren J; Blanton SH; Moran JJ; Lopez-Anido C; Morrow JM; Abreu L; Rizzo D; Kirk CA; Wu X; Feely S; Verhamme C; Saporta MA; Herrmann DN; Day JW; Sumner CJ; Lloyd TE; Li J; Yum SW; Taroni F; Baas F; Choi BO; Pareyson D; Scherer SS; Reilly MM; Shy ME; Züchner S;
Ann Neurol; 2019 Mar; 85(3):316-330. PubMed ID: 30706531
[TBL] [Abstract][Full Text] [Related]
2. Testing SIPA1L2 as a modifier of CMT1A using mouse models.
Murray GC; Hines TJ; Tadenev ALD; Xu I; Züchner S; Burgess RW
J Neuropathol Exp Neurol; 2024 Apr; 83(5):318-330. PubMed ID: 38472136
[TBL] [Abstract][Full Text] [Related]
3. Testing SIPA1L2 as a modifier of CMT1A using mouse models.
Murray GC; Hines TJ; Tadenev ALD; Xu I; Züchner S; Burgess RW
bioRxiv; 2023 Dec; ():. PubMed ID: 38076977
[TBL] [Abstract][Full Text] [Related]
4. Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study.
Tao F; Beecham GW; Rebelo AP; Blanton SH; Moran JJ; Lopez-Anido C; Svaren J; Abreu L; Rizzo D; Kirk CA; Wu X; Feely S; Verhamme C; Saporta MA; Herrmann DN; Day JW; Sumner CJ; Lloyd TE; Li J; Yum SW; Taroni F; Baas F; Choi BO; Pareyson D; Scherer SS; Reilly MM; Shy ME; Züchner S;
J Neuromuscul Dis; 2019; 6(2):201-211. PubMed ID: 30958311
[TBL] [Abstract][Full Text] [Related]
5. Charcot-Marie-Tooth disease and related inherited neuropathies.
Murakami T; Garcia CA; Reiter LT; Lupski JR
Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
[TBL] [Abstract][Full Text] [Related]
6. Peripheral myelin protein 22 gene duplication with atypical presentations: a new example of the wide spectrum of Charcot-Marie-Tooth 1A disease.
Mathis S; Corcia P; Tazir M; Camu W; Magdelaine C; Latour P; Biberon J; Guennoc AM; Richard L; Magy L; Funalot B; Vallat JM
Neuromuscul Disord; 2014 Jun; 24(6):524-8. PubMed ID: 24792522
[TBL] [Abstract][Full Text] [Related]
7. Duplication of the PMP22 gene in 17p partial trisomy patients with Charcot-Marie-Tooth type-1 neuropathy.
Roa BB; Greenberg F; Gunaratne P; Sauer CM; Lubinsky MS; Kozma C; Meck JM; Magenis RE; Shaffer LG; Lupski JR
Hum Genet; 1996 May; 97(5):642-9. PubMed ID: 8655146
[TBL] [Abstract][Full Text] [Related]
8. Association of miR-149 polymorphism with onset age and severity in Charcot-Marie-Tooth disease type 1A.
Nam SH; Kanwal S; Nam DE; Lee MH; Kang TH; Jung SC; Choi BO; Chung KW
Neuromuscul Disord; 2018 Jun; 28(6):502-507. PubMed ID: 29729827
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy.
Hanemann CO; Müller HW
Trends Neurosci; 1998 Jul; 21(7):282-6. PubMed ID: 9683317
[TBL] [Abstract][Full Text] [Related]
10. Charcot-Marie-Tooth phenotype produced by a duplicated PMP22 gene as part of a 17p trisomy-translocation to the X chromosome.
King PH; Waldrop R; Lupski JR; Shaffer LG
Clin Genet; 1998 Nov; 54(5):413-6. PubMed ID: 9842994
[TBL] [Abstract][Full Text] [Related]
11. Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease.
Grandis M; Leandri M; Vigo T; Cilli M; Sereda MW; Gherardi G; Benedetti L; Mancardi G; Abbruzzese M; Nave KA; Nobbio L; Schenone A
Exp Neurol; 2004 Nov; 190(1):213-23. PubMed ID: 15473994
[TBL] [Abstract][Full Text] [Related]
12. Increased severity over generations of Charcot-Marie-Tooth disease type 1A.
Steiner I; Gotkine M; Steiner-Birmanns B; Biran I; Silverstein S; Abeliovich D; Argov Z; Wirguin I
J Neurol; 2008 Jun; 255(6):813-9. PubMed ID: 18438698
[TBL] [Abstract][Full Text] [Related]
13. Electroceutical approach ameliorates intracellular PMP22 aggregation and promotes pro-myelinating pathways in a CMT1A in vitro model.
Intisar A; Woo H; Kang HG; Kim WH; Shin HY; Kim MY; Kim YS; Mo YJ; Lee YI; Kim MS
Biosens Bioelectron; 2023 Mar; 224():115055. PubMed ID: 36630746
[TBL] [Abstract][Full Text] [Related]
14. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
[TBL] [Abstract][Full Text] [Related]
15. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
Prukop T; Wernick S; Boussicault L; Ewers D; Jäger K; Adam J; Winter L; Quintes S; Linhoff L; Barrantes-Freer A; Bartl M; Czesnik D; Zschüntzsch J; Schmidt J; Primas G; Laffaire J; Rinaudo P; Brureau A; Nabirotchkin S; Schwab MH; Nave KA; Hajj R; Cohen D; Sereda MW
J Neurosci Res; 2020 Oct; 98(10):1933-1952. PubMed ID: 32588471
[TBL] [Abstract][Full Text] [Related]
16. Severe phenotypes in a Charcot-Marie-Tooth 1A patient with PMP22 triplication.
Kim SM; Lee J; Yoon BR; Kim YJ; Choi BO; Chung KW
J Hum Genet; 2015 Feb; 60(2):103-6. PubMed ID: 25500726
[TBL] [Abstract][Full Text] [Related]
17. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
[TBL] [Abstract][Full Text] [Related]
18. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases.
Birouk N; Gouider R; Le Guern E; Gugenheim M; Tardieu S; Maisonobe T; Le Forestier N; Agid Y; Brice A; Bouche P
Brain; 1997 May; 120 ( Pt 5)():813-23. PubMed ID: 9183252
[TBL] [Abstract][Full Text] [Related]
19. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.
Fledrich R; Schlotter-Weigel B; Schnizer TJ; Wichert SP; Stassart RM; Meyer zu Hörste G; Klink A; Weiss BG; Haag U; Walter MC; Rautenstrauss B; Paulus W; Rossner MJ; Sereda MW
Brain; 2012 Jan; 135(Pt 1):72-87. PubMed ID: 22189569
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
